

## **Zydus and Takeda enter into partnership to address emerging infectious diseases**

*Early stage project is to develop a vaccine for Chikungunya, often spread by the same mosquitoes which transmit Zika and Dengue*

---

*Ahmedabad, India, September 20, 2016*

Zydus Cadila, an innovation driven global healthcare provider and Takeda Pharmaceutical Company Limited [[TSE: 4502](#)], (“Takeda”), today announced a partnership to tackle chikungunya, an emerging infectious disease. The chikungunya virus is most often spread to people by *Aedes aegypti* and *Aedes albopictus* mosquitoes, the same vectors that spread dengue and zika. The broad-based agreement includes early stage development to the final commercialisation of the vaccine. There is currently no vaccine to prevent or medicine to treat chikungunya virus infection.

Chikungunya has been identified in over 60 countries in Asia, Africa, Europe and the Americas. After the bite of an infected mosquito, onset of illness occurs usually between 4 and 8 days but can range from 2 to 12 days. In some people, the joint pain may persist for months. People at risk for severe indications include newborns infected around the time of birth, older adults ( $\geq 65$  years), and people with medical conditions such as high blood pressure, diabetes, or heart disease.

Since 2005, India, Indonesia, Maldives, Myanmar and Thailand have reported over 1.9 million cases<sup>1</sup> and almost 1.3 million<sup>1</sup> suspected cases of Chikungunya being recorded in the Caribbean islands, Latin American countries, and the United States of America till 2015.

Speaking on this key development, Mr. Pankaj R. Patel, Chairman and Managing Director, Zydus group said, “We have always been committed to working with partners and collaborating to bring affordable therapies and bridge unmet healthcare needs. By partnering with Takeda on this very important research and development initiative and leveraging our development capabilities, we will be taking an all important step to prevent the disease burden which is highly prevalent in developing countries and causes suffering and disability.”

Dr. Rahul Singhvi, Takeda Vaccines’ Chief Operating Officer said, “Takeda is very pleased to work with Zydus Cadila. We are always open to tackling the world’s most urgent and neglected unmet medical needs together with partners. Our belief is that chikungunya can be prevented by vaccines, and that a vaccine might be licensed more quickly if we can accelerate development with this Zydus partnership.”

Dr. Singhvi added: “Takeda is at the center of important vaccine-related activities in global health and emerging infectious diseases. This is another demonstration of Takeda’s major commitment to the health of children in developing countries and elsewhere around the world.”

Terms of the agreement are not disclosed, but it is expected that this partnership will boost access to medicines in the future through this novel partnership.

## About Chikungunya

According to the Centers for Disease Control and Prevention (CDC), chikungunya virus is transmitted to people by mosquitoes. The most common symptoms of chikungunya virus infection are fever and joint pain. Other symptoms may include headache, muscle pain, joint swelling, or rash. Outbreaks have occurred in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. In late 2013, chikungunya virus was found for the first time in the Americas on islands in the Caribbean. There is a risk that the virus will be imported to new areas by infected travelers. There is currently no vaccine to prevent or medicine to treat chikungunya virus infection.<sup>2</sup>

## About Zydus Cadila

Zydus Cadila is an innovative global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies. The group employs over 19,000 people worldwide with 1200 scientists engaged in R & D. The Vaccine Technology Centre (VTC) is the vaccine research centre of the Zydus Group. The vaccine division has indigenously developed, manufactured and launched India's first vaccine against H1N1 (Vaxiflu-S) and has been developing vaccine candidates designed to address infectious diseases like next-generation Influenza, Leishmaniasis, Measles-Mumps-Rubella-Varicella, Typhoid, DPT-HiB, Hepatitis-B, Hepatitis-A, Hepatitis-E, Japanese Encephalitis, HPV and combination vaccines.

## Takeda's Commitment to Vaccines

Vaccines prevent more than two million deaths each year and have transformed global public health. For more than 60 years, Takeda has supplied vaccines to protect the health of people in Japan. Today, Takeda's global vaccine business is applying innovation to tackle some of the world's most challenging infectious diseases, such as dengue and norovirus. Our team brings an outstanding track record and a wealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline of vaccines to address some of the world's most pressing public health needs.

## About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit <http://www.takeda.com/news>.

## Contact:

For Zydus - Sujatha Rajesh; TEL: +9199740151180; [sujatha.rajesh@zyduscadila.com](mailto:sujatha.rajesh@zyduscadila.com)

For Takeda - Paul Newman; TEL: +1 617 444 4418; [paul.newman@takeda.com](mailto:paul.newman@takeda.com) -

###

<sup>1</sup><http://www.who.int/mediacentre/factsheets/fs327/en/>

<sup>2</sup> CDC <https://www.cdc.gov/chikungunya/>